Reported / Citable
Background
Meditech Development sued Solventum Corporation and 3M Company, alleging that their negative-pressure wound-therapy systems infringed two patents covering portable regulated vacuum-pump and pressure devices. The accused products included V.A.C. Therapy, Veraflo Therapy, Prevena Therapy, AbThera Therapy, V.A.C. Ulta units, related tubing, dressings, pads, sensors, and wound solutions.
Meditech asserted direct, induced, contributory, and willful infringement of U.S. Patent Nos. 9,138,216 and 9,186,444. It alleged that 3M employees had discussed the patents with Meditech in 2020 and that both defendants received an infringement letter in March 2026. Defendants moved to dismiss the complaint under Rule 12(b)(6).
The Court’s Holding
Judge Xavier Rodriguez granted the motion in part and denied it in part, dismissing all infringement claims without prejudice and allowing Meditech to amend by September 11, 2026. The court held that Meditech plausibly alleged the asserted positive-pressure and tamponade limitations, but not the valve limitation of the ’216 patent or the patient-monitoring-sensor and sensor-controlled agent-delivery limitations of the ’444 patent. Because each asserted claim lacked adequately pleaded limitations, Meditech had not stated direct infringement.
The court also dismissed the induced, contributory, and willful infringement theories. Although the allegations concerning promotional and instructional materials plausibly alleged affirmative inducement efforts and notice at least after the alleged communications, inducement still required an adequately pleaded underlying direct infringement claim. Contributory infringement was deficient for additional reasons, including insufficient allegations of knowledge of infringement and of no substantial noninfringing use. The willfulness allegations lacked factual detail showing knowledge of infringement and deliberate infringement, particularly as to Solventum following its 2024 spinoff from 3M.
Key Takeaways
- A patent complaint must plausibly allege that an accused product meets every limitation of each asserted claim, especially for complex medical-device systems.
- Alleging a generic valve or wound-pressure sensor did not adequately connect those components to the patents’ specific claimed functions.
- Pre-suit notice allegations should identify what products, patent claims, and allegedly infringing conduct were communicated, and should separately address each defendant’s knowledge.
Why It Matters
The order illustrates that detailed product descriptions alone may not sustain a patent case if the complaint does not supply a factual connection between each accused feature and each claim limitation. It also emphasizes the need to plead defendant-specific facts where corporate restructuring complicates attribution of knowledge.
The ruling leaves Meditech an opportunity to replead; it does not decide infringement on the merits or resolve claim-construction disputes. The court denied Meditech’s motion to compel without prejudice as moot because the complaint was dismissed.